ClinicalTrials.gg
TerminatedNCT01931566TOMMORROWUpdated Sep 16, 2019Results posted

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

A Phase 3 interventional study of Pioglitazone and Pioglitazone placebo in Mild Cognitive Impairment Due to Alzheimer's Disease, sponsored by Takeda. Terminated at 55 sites in 5 countries. Open to participants aged 65 Years to 83 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-16.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of efficacy of the drug; no safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,494
Allocation
Randomized
Ages
65 Years to 83 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
19th of 1,611
3,494 · median 73
Started
2013
with 55 others
Phase 3
188 of 1,942
19 open now
Registered
591st of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 19th largest by enrollment of the 1,611 interventional ones that give a count, is one of 56 that started in 2013, is one of 188 in phase 3, and was the 591st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 83 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.

Read the detailed description

This study has two goals. One of these goals is to see if a new genetic test can determine if participants are at risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) within the next five years. The other goal is to evaluate the study drug called pioglitazone. Pioglitazone is being tested to delay the onset of MCI-AD. This study will look at the effectiveness of pioglitazone in delaying the onset of MCI-AD in cognitively-normal people who are at high-risk of developing MCI-AD, as identified by the biomarker in the non-Hispanic/Latino Caucasian participants.

This multi-centre trial will be conducted worldwide. The study will enroll approximately 3500 subjects. Participants will be assigned to high or low risk groups for developing MCI- AD within the next five years, based on the results of the biomarker risk algorithm. Participants in the high risk group will be randomly assigned to one of the two treatment groups-which will remain unknown to the participant and study doctor during the study (unless there is an urgent medical need):

  • Pioglitazone tablet
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient.

Participants in the low risk group will be assigned to placebo. The assignment of each participant to the high or low risk group, as well as the participant's treatment assignment, will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need).

All participants will be asked to take one tablet at the same time each day throughout the study.

The overall time to participate in this study is approximately 5 years. Participants will make up to 14 visits to the clinic, and will be contacted by telephone 3 months after each treatment visit for a follow-up assessment, and 2 weeks after the final visit.

03

Conditions studied

  • Mild Cognitive Impairment Due to Alzheimer's Disease

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
65 Years to 83 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, participant is capable of understanding and complying with protocol requirements.
  2. Signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is able to physically perform the cognitive tests in the opinion of the investigator and is fluent in the language that tests will be administered.
  4. Is cognitively normal at baseline, scoring as indicated for the following tests:

    • Clinical Dementia Rating (CDR)=0.
    • At least one memory test above -1.5 standard deviation (SD) of the demographically corrected normative mean.
  5. Must score ≥25 on the (MMSE) at the screening visit after the education and age adjustment.
  6. Is male or female between the ages of 65 and 83 years, inclusive, at time of the Screening visit.
  7. Has the ability and intention to participate in regular study visits, in the opinion of the Investigator.
  8. Has a project partner who can separately complete an Acknowledgement Form on his/her own behalf and take part in the study (with the intent to do so as long as the participant is enrolled) to provide information on the cognitive, functional, and behavioral status of the participant and to assist with monitoring of study medication, if needed.

Exclusion criteria

Exclusion Criteria:

  1. Has a current diagnosis or history of any type of cognitive impairment or dementia or has a current diagnosis or history of neurological/psychiatric disorder or any other diagnosis that significantly affects cognitive performance (eg, mental retardation, organic mental disorder).
  2. Has a current diagnosis of significant psychiatric illness, per Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition - Text Revision () (or DSM-V when published) (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the participant has a current diagnosis or history of schizophrenia or bipolar disorder.
  3. Has a glycosylated () >8.0% at the time of baseline or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist. The participant should be on a stable antidiabetic regimen for at least 3 months prior to enrollment.
  4. Has a unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. History of infection is considered exclusionary for this study.
  5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse/dependence within 2 years prior to the Screening Visit.
  6. Is an immediate family member, testing center employee, or is in a dependent relationship with a testing center employee who is involved in conduct of this study (eg, spouse, parent, child, and sibling) or may consent under duress.
  7. Has a history of or allergies to pioglitazone or related compounds.
  8. Is required to take excluded medications as specified in the Excluded Medications Section.
  9. Had any of the following values at the Baseline Visit (Visit 2):

    1. A serum total value >1.5× (ULN).
    2. A serum (ALT) or aspartate aminotransferase (AST) value >2xULN.
    3. Unexplained microscopic/macroscopic hematuria on one repeat examinations within 2 weeks of the initial assessment.
  10. Is positive for either surface antigen (HBsAg) or anti- virus (HCV) antibodies at the Baseline Visit (Visit 2).
  11. Has a condition or takes medication that, in the opinion of the Investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the participant from adequately participating in the study or continue for the anticipated duration of the study.
  12. Has received any compound within 30 days prior to screening or 5 half-lives prior to Screening or is currently participating in another study which entails the administration of an investigational or marketed drug, supplement or intervention including, but not limited to diet, exercise, lifestyle or invasive procedure.
  13. Has a history of any cancer that has been in remission for less than 2 years from the Screening Visit. Participants with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Participants with history of bladder cancer are not eligible irrespective of the remission status.
  14. Has a history or current diagnosis of macular edema or macular degeneration.
  15. If female, has a history of fractures with no or minimal trauma (eg, wrist, hip, lumbar or thoracic vertebral fracture).
  16. Has a history or current diagnosis of congestive heart failure (CHF), Class III-IV.
  17. Has been exposed to the cognitive tests performed in this study within 6 months prior to the Screening Visit, with the exception of the .
  18. Participant's Translocase of the Outer Mitochondrial Membrane 40 homolog (TOMM40) rs10524523 or apolipoprotein E (APOE) genotypes or APOE phenotype are known by the participant or the study staff participating in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,494 participants (actual)

Study arms

  • Placebo comparator
    Low Risk Placebo

    Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.

    Drug: Pioglitazone placebo

  • Placebo comparator
    High Risk Placebo

    Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.

    Drug: Pioglitazone placebo

  • Experimental
    High Risk Pioglitazone

    Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.

    Drug: Pioglitazone

Interventions

  • Pioglitazone SR tablets

  • DrugPioglitazone placebo

    Pioglitazone placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants

    The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time.

    Time frame: Baseline to the end of study (approximately up to 5 years)

  2. Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants

    The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time.

    Time frame: Baseline to the end of study (approximately up to 5 years)

Secondary outcomes

  1. Change From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum

    Composite scores derived from the test battery. Domains of Episodic Memory \[California Verbal Learning Test-2nd Edition (CVLT-II), Brief Visuospatial Memory Test-Revised (BVMT-R)\]; Executive Function \[Trail Making Test (TMT) (Part B), Wechsler Adult Intelligence Scale (WAIS)-III Digit Span Test-backwards span\]; Language \[Multilingual Naming Test (MiNT), Semantic Fluency (animals), Lexical/phonemic fluency (F, A, and S in English; D, S, and F in German)\]; and Attention \[WAIS-III Digit Span Test-forward span, TMT (Part A)\] used for composite score. 12 measures were derived from 8 neuropsychological tests. CVLT-II test involved 2 primary measures (short, long delay recall); BVMT-R had 2 measures (copy and recall); Digit Span and Trail both had 2 measures (forward and backward span and Parts A and B). There was 1 total score for each test: CDT, MINT, semantic and lexical fluency. Total score ranged from -1.222 to 1.707 at baseline, a higher composite score indicated better cognition.

    Time frame: Baseline and Month 48

  2. Change From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum

    The ADCS ADL-PI is a functional measure that was specifically designed for standardized administration over long duration clinical studies to prevent AD. The ADCS ADL-PI is a 20-item instrument that included 15 ADL questions, which were scored as 1 (with a lot of difficulty), 2 (with some difficulty), or 3 (as well as usually, with no difficulty), plus 5 vision, hearing, and mobility questions, which were scored from 0 (no) to 1 (yes). ADL Total ranged from 0 to 45, and lower scores indicated greater disability.

    Time frame: Baseline and Month 48

07

Results

Posted Aug 14, 2019

Participant flow

Participants took part in the study at 57 investigative sites in United States, United Kingdom, Germany, Australia, and Switzerland from 01 Aug 2013 to 06 Sep 2018.

Participant flow — Overall Study
MilestoneLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
Started43315161545
Treated42715071531
Completed44039
Not completed42914761506
Withdrew: Randomized but not treated6914
Withdrew: Adverse event37167132
Withdrew: Major protocol deviation51421
Withdrew: Lost to follow-up32623
Withdrew: Voluntary withdrawal78245225
Withdrew: Study termination2899681037
Withdrew: Reason not specified114753
Withdrew: Missing001

Outcome measures

PrimaryTime to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants

The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time.

Time frame:
Baseline to the end of study (approximately up to 5 years)
Reported as:
Mean · days
Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants
daysLow Risk PlaceboHigh Risk Placebo
Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian Participants905.44 (189.00 to 909.00)1238.67 (168.00 to 1268.00)
Statistical analysis
  • Low Risk Placebo vs High Risk Placebo · Regression, Cox · p = 0.023
PrimaryTime to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants

The event definition for MCI-AD was the time in days from the randomization date to the date of the first of two consecutive scheduled visits at which a participant was assessed with a diagnosis of MCI due to AD confirmed by adjudication committee. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to the largest event time.

Time frame:
Baseline to the end of study (approximately up to 5 years)
Reported as:
Mean · days
Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants
daysHigh Risk PlaceboHigh Risk Pioglitazone
Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian Participants1238.67 (168.00 to 1268.00)1261.24 (168.00 to 1285.00)
Statistical analysis
  • High Risk Placebo vs High Risk Pioglitazone · Regression, Cox · p = 0.307
SecondaryChange From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum

Composite scores derived from the test battery. Domains of Episodic Memory \[California Verbal Learning Test-2nd Edition (CVLT-II), Brief Visuospatial Memory Test-Revised (BVMT-R)\]; Executive Function \[Trail Making Test (TMT) (Part B), Wechsler Adult Intelligence Scale (WAIS)-III Digit Span Test-backwards span\]; Language \[Multilingual Naming Test (MiNT), Semantic Fluency (animals), Lexical/phonemic fluency (F, A, and S in English; D, S, and F in German)\]; and Attention \[WAIS-III Digit Span Test-forward span, TMT (Part A)\] used for composite score. 12 measures were derived from 8 neuropsychological tests. CVLT-II test involved 2 primary measures (short, long delay recall); BVMT-R had 2 measures (copy and recall); Digit Span and Trail both had 2 measures (forward and backward span and Parts A and B). There was 1 total score for each test: CDT, MINT, semantic and lexical fluency. Total score ranged from -1.222 to 1.707 at baseline, a higher composite score indicated better cognition.

Time frame:
Baseline and Month 48
Reported as:
Mean · score on a scale
Change From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum
score on a scaleHigh Risk PlaceboHigh Risk Pioglitazone
Change From Baseline for Cognitive Decline on Composite Score on the Cognitive Test Battery for Pioglitazone-treated Participants Versus Placebo-treated Participants in the High-risk Stratum0.1841 ± 0.275080.1687 ± 0.40621
SecondaryChange From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum

The ADCS ADL-PI is a functional measure that was specifically designed for standardized administration over long duration clinical studies to prevent AD. The ADCS ADL-PI is a 20-item instrument that included 15 ADL questions, which were scored as 1 (with a lot of difficulty), 2 (with some difficulty), or 3 (as well as usually, with no difficulty), plus 5 vision, hearing, and mobility questions, which were scored from 0 (no) to 1 (yes). ADL Total ranged from 0 to 45, and lower scores indicated greater disability.

Time frame:
Baseline and Month 48
Reported as:
Mean · score on a scale
Change From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum
score on a scaleHigh Risk PlaceboHigh Risk Pioglitazone
Change From Baseline in Instrumental Activities of Daily Living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) Between Pioglitazone-treated and Placebo-treated Groups of the High-risk Stratum0.1 ± 4.930.3 ± 5.32

Adverse events

Collected over Baseline up to 30 days after the last dose of study drug (up to 935 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Risk Placebo2/427 (0.5%)81/427 (19%)235/427 (55%)
High Risk Placebo21/1,507 (1.4%)404/1,507 (26.8%)828/1,507 (54.9%)
High Risk Pioglitazone7/1,531 (0.5%)358/1,531 (23.4%)822/1,531 (53.7%)
Most frequent serious events
Showing 10 of 422
Most frequent serious events
EventLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
OsteoarthritisMusculoskeletal and connective tissue disorders4/42722/150723/1531
Atrial fibrillationCardiac disorders5/42715/150716/1531
PneumoniaInfections and infestations3/42712/150715/1531
SyncopeNervous system disorders2/42713/150714/1531
Myocardial infarctionCardiac disorders0/42713/15073/1531
ArthralgiaMusculoskeletal and connective tissue disorders3/42713/150710/1531
Transient ischaemic attackNervous system disorders0/42711/150710/1531
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/4279/150711/1531
Angina pectorisCardiac disorders3/42710/15076/1531
DiverticulitisInfections and infestations3/4277/15074/1531
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLow Risk PlaceboHigh Risk PlaceboHigh Risk Pioglitazone
Upper respiratory tract infectionInfections and infestations62/427190/1507183/1531
Urinary tract infectionInfections and infestations47/427178/1507191/1531
ArthralgiaMusculoskeletal and connective tissue disorders45/427125/1507125/1531
FallInjury, poisoning and procedural complications18/427143/1507135/1531
CataractEye disorders27/427119/1507106/1531
Back painMusculoskeletal and connective tissue disorders31/42782/1507101/1531
HypertensionVascular disorders26/42797/150793/1531
NasopharyngitisInfections and infestations22/42772/150790/1531
ConstipationGastrointestinal disorders24/42770/150772/1531
OsteoarthritisMusculoskeletal and connective tissue disorders19/42781/150786/1531

Baseline characteristics

Randomized Set included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Mean70.3 ± 4.0274.6 ± 5.2774.4 ± 5.2574.0 ± 5.31
Age, Customized
Age, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
<75 years3606326581650
>=75 years738848871844
Sex: Female, Male
Sex: Female, Male(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Female2598508121921
Male1746667331573
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Hispanic or Latino8191239
Not Hispanic or Latino425149715333455
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
American Indian or Alaska Native0044
Asian1101425
Black or African American10383987
Native Hawaiian or Other Pacific Islander0112
White421146314843368
Multiracial1438
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
Non-Hispanic/Latino Caucasian413144414723329
Hispanic/Latino and/or non-Caucasian207273165
Region of Enrollment
Region of Enrollment(Participants)Low Risk PlaceboHigh Risk PlaceboHigh Risk PioglitazoneTotal
United States2709629852217
United Kingdom102311315728
Australia56215218489
Switzerland3181839
Germany210921
08

Study locations

55 sites
  • Phoenix, Arizona, United States
  • Sun City, Arizona, United States
  • Long Beach, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Delray Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Lady Lake, Florida, United States
  • Lake Worth, Florida, United States
  • Merritt Island, Florida, United States
  • Orlando, Florida, United States
  • Port Orange, Florida, United States
  • Saint Petersburg, Florida, United States
  • Weston, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • Chicago, Illinois, United States
  • Elk Grove Village, Illinois, United States
  • Elk Grove, Illinois, United States
  • Iowa City, Iowa, United States
  • Farmington Hills, Michigan, United States
  • Saint Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Marlton, New Jersey, United States
  • New York, New York, United States
  • Concord, North Carolina, United States
  • Durham, North Carolina, United States
  • Akron, Ohio, United States
  • Portland, Oregon, United States
  • Charleston, South Carolina, United States
  • Cordova, Tennessee, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Middleton, Wisconsin, United States
  • North Ryde, New South Wales, Australia
  • Southport, Queensland, Australia
  • West Heidelberg, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Stuttgart, Baden Wuerttemberg, Germany
  • Siegen, Nordrhein Westfalen, Germany
  • Halle, Sachsen Anhalt, Germany
  • Berlin, Germany
  • Basel, Switzerland
  • Exeter, Devon, United Kingdom
  • Plymouth, Devon, United Kingdom
  • Hammersmith, Greater London, United Kingdom
  • London, Greater London, United Kingdom
  • Manchester, Greater Manchester, United Kingdom
  • Salford, Greater Manchester, United Kingdom
  • Blackpool, Lancashire, United Kingdom
  • Isleworth, Middlesex, United Kingdom
  • Glasgow, Strathclyde, United Kingdom
  • Dundee, Tayside Region, United Kingdom
  • Perth, Tayside Region, United Kingdom
  • Bristol, United Kingdom
09

References and documents

Publications

  • Burns DK, Alexander RC, Welsh-Bohmer KA, Culp M, Chiang C, O'Neil J, Evans RM, Harrigan P, Plassman BL, Burke JR, Wu J, Lutz MW, Haneline S, Schwarz AJ, Schneider LS, Yaffe K, Saunders AM, Ratti E; TOMMORROW study investigators. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. PubMed 34146512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Jul 2018, 59 months.

Results were first posted in Aug 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2013
First posted
Aug 29, 2013
StartActual
Aug 1, 2013
Primary completionActual
Jul 24, 2018
CompletionActual
Sep 6, 2018
Results first posted
Aug 14, 2019
Last update
Sep 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01931566
Lead sponsor
Takeda
Collaborators
Zinfandel Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Aug 29, 2013
Start date
Aug 1, 2013
Primary completion
Jul 24, 2018
Completion
Sep 6, 2018
Results posted
Aug 14, 2019
Last update
Sep 16, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion